Skip to content

Efficacy of Vitamin D on Vulvovaginal Atrophy in Menopausal Women

Efficacy of Vitamin D on Vulvovaginal Atrophy in Menopausal Women: A Randomized Controlled Trial

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20231107003
Enrollment
48
Registered
2023-11-07
Start date
2023-07-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menopausal women who have vulvovaginal atrophy vulvovaginal atrophy, menopausal women , vitamin D, vaginal maturation value, vaginal atrophy symptoms (The most bothersome symptom), modified vaginal health index , vaginal atrophy score , vitamin D level

Interventions

ergocalciferol 20000 IU 1 cap po q monday, wednesday, friday * 12 weeks,placebo 1 cap po q monday, wednesday, friday * 12 weeks
Active Comparator Drug,Placebo Comparator No treatment

Sponsors

Maharat Nakhon Ratchasima Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Women who have vulvovaginal atrophy symptoms, 2. Menopausal women, who absence of menstruation for at least 1 year, 3. Women who previous bilateral oophorectomy, 4. Women who have serum FSH level more than 40 IU/L

Exclusion criteria

Exclusion criteria: 1. Women who have history of hormonal or vitamin D treatments or supplement within a previous 12 weeks, 2. Women who have abnormal pap smear, 3. Women who have active sexual transmitted disease, 4. Women who have abnormal uterine bleeding, 5. women who have severe medical condition (e.g. liver failure, renal failure), 6. women who have history of vitamin D or calcium allergy, 7. Unwillingness to participate in the study

Design outcomes

Primary

MeasureTime frame
vaginal maturation value 12 weeks VMV was determined from cells collected from the upper one-third of the bilateral vaginal wall using the liquid-based technique and cytologis will report

Secondary

MeasureTime frame
vaginal atrophy symptoms (The most bothersome symptom) 0, 6, 12 weeks Patient reported outcome using a questionnaire interview,modified vaginal health index 0, 6, 12 weeks Physical examination,vaginal atrophy score 0, 6, 12 weeks Physical examination ,vitamin D level 0, 6, 12 weeks Electrochemiluminescence immunoassay (ECLIA),Vaginal pH 0, 6, 12 weeks using acid test strips

Countries

Thailand

Contacts

Public ContactChirocha Hengphrathani

Maharat Nakhon Ratchasima Hospital

chirocha-first@hotmail.com0874543888

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026